open access

Vol 87, No 5 (2016)
Research paper
Published online: 2016-06-02
Get Citation

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles

İsmet Gün, Özkan Özdamar, Sadık Şahin, Elçin Çetingöz, Kenan Sofuoğlu
DOI: 10.5603/GP.2016.0007
·
Pubmed: 27304654
·
Ginekol Pol 2016;87(5):372-377.

open access

Vol 87, No 5 (2016)
ORIGINAL PAPERS Obstetrics
Published online: 2016-06-02

Abstract

Objectives: The aim of the study was to investigate the effects of two different vaginal progesterone forms, administered for luteal phase support, on pregnancy outcomes in normoresponder women aged < 35, who underwent long agonist IVF/ICSI-ET cycles.

Material and methods: A retrospective cohort analysis was designed. Normoresponders with primary infertility, who un­derwent IVF/ICSI-ET cycles employing GnRH analogue and who received progesterone as either capsule or gel form for LPS following a single embryo transfer, were analyzed. The cycles were categorized into two groups: micronized progesterone vaginal capsule 600 mg/day (Group 1, n = 78) and progesterone vaginal gel 180 mg/day (Group 2, n = 99). Positive β-hCG, clinical pregnancy and ongoing pregnancy rates were analyzed.

Results: Both, demographic and stimulation characteristics were comparable between the groups. No difference was observed between the capsule and the gel groups regarding positive β-hCG (33.3% and 28.3%, respectively; p = 0.580), clinical pregnancy (26.9% and 22.2%, respectively; p = 0.584), and ongoing pregnancy rates (21.8% and 20.2%, respectively; p = 0.942) after treatment completion.

Conclusions: In long agonist IVF/ICSI-ET cycles, positive β-hCG, clinical pregnancy and ongoing pregnancy rates do not significantly differ between normoresponder patients receiving micronized progesterone vaginal capsule and those receiv­ing progesterone vaginal gel for LPS.

Abstract

Objectives: The aim of the study was to investigate the effects of two different vaginal progesterone forms, administered for luteal phase support, on pregnancy outcomes in normoresponder women aged < 35, who underwent long agonist IVF/ICSI-ET cycles.

Material and methods: A retrospective cohort analysis was designed. Normoresponders with primary infertility, who un­derwent IVF/ICSI-ET cycles employing GnRH analogue and who received progesterone as either capsule or gel form for LPS following a single embryo transfer, were analyzed. The cycles were categorized into two groups: micronized progesterone vaginal capsule 600 mg/day (Group 1, n = 78) and progesterone vaginal gel 180 mg/day (Group 2, n = 99). Positive β-hCG, clinical pregnancy and ongoing pregnancy rates were analyzed.

Results: Both, demographic and stimulation characteristics were comparable between the groups. No difference was observed between the capsule and the gel groups regarding positive β-hCG (33.3% and 28.3%, respectively; p = 0.580), clinical pregnancy (26.9% and 22.2%, respectively; p = 0.584), and ongoing pregnancy rates (21.8% and 20.2%, respectively; p = 0.942) after treatment completion.

Conclusions: In long agonist IVF/ICSI-ET cycles, positive β-hCG, clinical pregnancy and ongoing pregnancy rates do not significantly differ between normoresponder patients receiving micronized progesterone vaginal capsule and those receiv­ing progesterone vaginal gel for LPS.

Get Citation

Keywords

progesterone, vaginal gel, vaginal capsule, long agonist protocol, in vitro fertilization

About this article
Title

Progesterone vaginal capsule versus vaginal gel for luteal support in normoresponder women undergoing long agonist IVF/ICSI cycles

Journal

Ginekologia Polska

Issue

Vol 87, No 5 (2016)

Article type

Research paper

Pages

372-377

Published online

2016-06-02

DOI

10.5603/GP.2016.0007

Pubmed

27304654

Bibliographic record

Ginekol Pol 2016;87(5):372-377.

Keywords

progesterone
vaginal gel
vaginal capsule
long agonist protocol
in vitro fertilization

Authors

İsmet Gün
Özkan Özdamar
Sadık Şahin
Elçin Çetingöz
Kenan Sofuoğlu

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl